Impact of screening and early detection of impaired fasting glucose tolerance and type 2 diabetes in Canada: A Markov model simulation

ClinicoEconomics and Outcomes Research

Volumn 4, Issue 1, 2012, Pages 91-97

  Mortaz, Soroush ^a   Wessman, Christine ^a   Duncan, Ross ^a   Gray, Rachel ^a   Badawi, Alaa ^a  

^a PUBLIC HEALTH AGENCY OF CANADA   (Canada)

Author keywords

Cost effectiveness; Economic analysis; Markov model; Qualityadjusted life years; Type 2 diabetes

Indexed keywords

METFORMIN;

ADULT; ARTICLE; ASYMPTOMATIC DISEASE; CANADA; COHORT ANALYSIS; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; COST UTILITY ANALYSIS; DRUG COST; EARLY DIAGNOSIS; HEALTH CARE COST; HUMAN; IMPAIRED GLUCOSE TOLERANCE; LIFESTYLE MODIFICATION; NON INSULIN DEPENDENT DIABETES MELLITUS; QUALITY ADJUSTED LIFE YEAR; RISK ASSESSMENT; SCREENING TEST;

EID: 84930473786     PISSN: None     EISSN: 11786981     Source Type: Journal    
DOI: 10.2147/CEOR.S30547     Document Type: Article

References (29)

1. World Health Organization. Diabetes. Fact sheet Number 312, August 2011. Available at: http://www.who.int/mediacentre/factsheets/ fs312/en/index.html. Accessed January 15, 2012.
2. Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract. 2010; 87(1):4-14.
3. Gillies CL, Lambert PC, Abrams KR, et al. Different strategies for screening and prevention of type 2 diabetes in adults: cost effectiveness analysis. Br Med J. 2008;336(7654):1180-1185.
4. Feig DS, Palda VA, Lipscombe L; Canadian Task Force on Preventive Health Care. Screening for type 2 diabetes mellitus to prevent vascular complications: updated recommendations from the Canadian Task Force on Preventive Health Care. CMAJ. 2005;172(2):177-180.
5. Canadian Diabetes Association. 2008 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada. Canad J Diab. 2008;32 Suppl 1:S14-S17.
6. Badawi A, Klip A, Haddad P, et al. Type 2 diabetes mellitus and inflammation: prospects for biomarkers of risk and nutritional intervention. Diabetes Metab Synd Obes. 2010;3:173-186.
7. Hoerger TJ, Harris R, Hicks KA, Donahue K, Sorensen S, Engelgau M. Screening for type 2 diabetes mellitus: a cost-effectiveness analysis. Ann Intern Med. 2004;140(9):689-699.
8. Goyder EC, Irwig LM. Screening for type 2 diabetes mellitus: a decision analytic approach. Diabet Med. 2000;17(6):469-477.
9. Li R, Zhang P, Barker LE, Chowdhury FM, Zhang X. Cost-effectiveness of interventions to prevent and control diabetes mellitus: a systematic review. Diabetes Care. 2010;33(8):1872-1894.
10. Raikou M, McGuire A. The economics of screening and treatment in type 2 diabetes mellitus. Pharmacoeconomics. 2003;21(8):543-564.
11. Hoerger TJ, Hicks KA, Sorensen SW, et al. Cost-effectiveness of screening for pre-diabetes among overweight and obese. Diabetes Res. 2007;30(11):2875-2879.
12. Wilson SE, Rosella LC, Lipscombe LL, Manuel DG. The effectiveness and efficiency of diabetes screening in Ontario, Canada: a populationbased cohort study. BMC Public Health. 2010;10(1):506.
13. Hux JE, Ivis F, Flintoft V, Bica A. Diabetes in Ontario: Determination of prevalence and incidence using a validated administrative data algorithm. Diabetes Care. 2001;25(3):512-516.
14. Palmer AJ, Roze S, Valentine WJ, Spinas GA, Shaw JE, Zimmet PZ. Intensive lifestyle changes or metformin in patients with impaired glucose tolerance: modeling the long-term health economic implications of the diabetes prevention program in Australia, France, Germany, Switzerland, and the United Kingdom. Clin Ther. 2004;26(2): 304-321.
15. Rasmussen S, Glumer C, Sandbaek A, Lauritzen T, Borch-Johnsen K. Progression from impaired fasting glucose and impaired glucose tolerance to diabetes in a high-risk screening programme in general practice: the ADDITION study, Denmark. Diabetologia. 2006;50(2): 293-297.
16. O'Reilly D, Hopkins R, Blackhouse G, Hux J, Dolovich L. Development of an Ontario Diabetes Economic Model (ODEM) and Application to a Multidisciplinary Primary Care Diabetes Management Program. Report Prepared for the Ontario Ministry of Health and Long-term Care. 2006.
17. Hernan WH, Hoerger TJ, Brandle M, et al; Diabetes Prevention Program Research Group The cost-effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance. Ann Intern Med. 2005;142(5):323-332.
18. Meigs J, Muller D, Nathan D, Blake D, Andres R. Baltimore Longitudinal Study. The natural history of progression from normal glucose tolerance to type 2 diabetes in the Baltimore longitudinal study of aging. Diabetes. 2003;52(6):1475-1484.
19. Bonora E, Kiechl S, Willeit J, Oberhollenzer F, Egger G. Populationbased incidence rates and risk factors for type 2 diabetes in white individuals: the Bruneck study. Diabetes. 2004;53(7):1782-1789.
20. Davies M, Tringham J, Jarvis J, Skinner TC, Farooqi AM, Khunti K. Systematic screening for type 2 diabetes mellitus: results of a large population based study targeting those with conventional risk factors. Diabet Med. 2005;22 Suppl 2:99.
21. Zhang Y, Engelgoan M, Valdez R. Efficient cutoff points for three screening tests for detecting undiagnosed diabetes and pre-diabetes. Diabetes Care. 2005;28(6):1321-1325.
22. Avenell A, Broom J, Brown T, et al. Systematic review of the longterm effects and economic consequences of treatments for obesity and implications for health improvement. Health Technol Assess. 2004; 8(21):iii-iv, 1-182.
23. Hernan WH, Brandle M, Zhang P, et al. Diabetes Prevention Program Research Group. Costs associated with the primary prevention of type 2 diabetes mellitus in the diabetes prevention program. Diabetes Care. 2003;26(1):36-47.
24. Clarke P, Gray A, Holman R. Estimating utility values for health states of type 2 diabetic patients using the EQ-5D (UKPDS 62). Med Decis Making. 2002;22(4):340-349.
25. Waugh N, Scotland G, McNamee P, et al. Screening for type 2 diabetes: literature review and economic modelling. Health Technol Assess. 2007; 11(17):iii-iv, ix-xi, 1-125.
26. Tarride J-E, Hopkins R, Blackhouse G, et al. A review of methods used in long-term cost-effectiveness models of diabetes mellitus treatment. Pharmacoeconomics. 2010;28(4):255-277.
27. Chatterjee R, Narayan KMV, Lipscomb J, Phillips LS. Screening adults for pre-diabetes and diabetes may be cost-saving. Diabetes Care. 2010; 33(7):1484-1490.
28. American Diabetes Association. Implications of the United Kingdom Prospective Diabetes Study. Diabetes Care. 2003;26 Suppl 1: S28-S32.
29. Schaufler TM, Wolff M. Cost effectiveness of preventive screening for type-2-diabetes mellitus in Germany. Appl Health Econ Health Policy. 2010;8(3):191-202.